Everything below concerns HPLC-UV. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-07-28. Numbers and descriptions here follow the published literature rather than marketing material.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule ligand; not a hormone or peptide |
| Molecular formula | C20H24ClN3O4S | Reported for the free base |
| CAS Registry Number | 1379686-30-2 | Unique chemical identifier |
| Common synonyms | SR9009; stenabolic | Stenabolic is informal and not an official name |
| Reported targets | REV-ERBα and REV-ERBβ | Nuclear receptors linked to circadian and metabolic regulation |
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
Thomas Bellchambers (born 9 July 1989) is a former professional Australian rules footballer who played for the Essendon Football Club in the Australian Football League (AFL). He is a current professional boxer. After playing for the Tasmanian Devils in the TAC Cup, he was drafted with pick 8 in the 2007 pre-season draft. He made his debut against Hawthorn in Round 11 of the 2008 AFL season. He announced his retirement from the AFL on the 15th of September 2020. Bellchambers, along with 33 other Essendon players, was found guilty of using a banned performance-enhancing substance, thymosin beta-4, as part of Essendon's sports supplements program during the 2012 season. He and his team-mates were initially found not guilty in March 2015 by the AFL Anti-Doping Tribunal, but a guilty verdict was returned in January 2016 after an appeal by the World Anti-Doping Agency. He was suspended for two years which, with backdating, ended in November 2016; as a result, he served approximately fourteen months of his suspension and missed the entire 2016 AFL season. He announced his retirement on 15 September 2020, after 136 games. On 24/05/23 Bellchambers made his professional boxing debut Vs Cameron Mooney in Melbourne, Bellchambers won by KO in the 3rd round. The fight was in the heavyweight division. Bellchambers professional boxing record is 1-0. (1 by KO)
Clark University 1909 Fordham University 1912 Harvard University 1936 University of Allahabad 1937 University of Benares 1937 University of Calcutta 1938 University of Oxford 1938 University of Geneva 1945 Swiss Federal Institute of Technology in Zurich 1955 on his 80th birthday In addition, he was:
Although with only one exception (the amoeboid Paulinella chromatophora), all chloroplasts can be traced back to a single endosymbiotic event they can be found in extremely diverse organisms that are not directly related to each other—a consequence of many secondary and even tertiary endosymbiotic events.
After Ceaușescu left, the mood of the crowds in Palace Square grew celebratory, perhaps even more than in the other former Eastern Bloc countries because of the recent violence. People cried, shouted and gave each other gifts mainly because it was also close to Christmas Day, a long-suppressed holiday in Romania. The occupation of the Central Committee building continued. People threw Ceaușescu's writings, official portraits and propaganda books out the windows, intending to burn them. They also promptly ripped off the giant letters from the roof making up the word "comunist" ("communist") in the slogan: "Trăiască Partidul Comunist Român!" ("Long live the Communist Party of Romania!"). A young woman appeared on the rooftop and waved a flag with the coat of arms torn out. At that time, fierce fights were underway at Bucharest Otopeni International Airport between troops sent against each other with the claim that they were going to confront terrorists. Early in the morning, troops sent to reinforce the airport were fired upon. These troops were from the UM 0865 Câmpina military base, and were summoned there by General Ion Rus, commander of the Romanian Air Force. The confrontation resulted in the deaths of 40 soldiers, as well as eight civilians. The military trucks were allowed entrance into the airport's perimeter, passing several checkpoints. However, after passing the last checkpoint, they were fired upon from different directions. A civilian bus was also fired upon during the firefight.
Sources: en.wikipedia.org
Mean Green – Big, bold flavor inspired by the original black and green Monster Energy can. White Haze – A smooth, citrusy flavor with a clean finish. Peach Perfect – A crisp and refreshing peach blend. Scary Berries – A sparkling citrus and berry mix with less sweetness. Killer Sunrise – A bold citrus punch designed for all-day partying. Gnarly Grape – A juicy grape flavor with a bold finish. Pink Poison – A sweet and tangy blend with a vibrant profile. Later in 2023, Monster introduced the Nasty Beast line, a series of hard iced tea beverages targeting the flavored malt beverage market and competing with brands like Twisted Tea. Like The Beast Unleashed, these contain 6.0% ABV. Nasty Beast flavors include:
Grand Cordon: Badge worn from a sash over the right shoulder, with a star on the left chest. Grand Officer: Badge worn around the neck, with a smaller star on the left chest. Commander: Badge worn around the neck. Officer: Badge worn on the left chest from a ribbon bearing a rosette. Knight: Badge worn on the left chest from a plain ribbon.
Vitamin K2 or menaquinone (MK) () is one of three types of vitamin K, the other two being vitamin K1 (phylloquinone) and K3 (menadione). K2 is both a tissue and bacterial product (derived from vitamin K1 in both cases) and is usually found in animal products or fermented foods. The number n of isoprenyl units in their side chain differs and ranges from 4 to 13, hence vitamin K2 consists of various forms. It is indicated as a suffix (-n), e. g. MK-7 or MK-9.
Sources: en.wikipedia.org
"Fentanyl". U.S. Drug Enforcement Administration (DEA). "Fentanyl". European Union Drugs Agency (EUDA). "Fentanyl". National Institute on Drug Abuse (NIDA). 21 December 2021. Archived from the original on 6 June 2022. Fentanyl (Report). National Institute for Occupational Safety and Health (NIOSH). 8 July 2021.
=== ZonaZoo === Officially implemented in 2003, ZonaZoo is the official student section and student ticketing program for the University of Arizona Athletics. The ZonaZoo program is co-owned by the Associated Students of the University of Arizona (ASUA) and Arizona Athletics yet run by a team of individuals called the ZonaZoo Crew. In 2014, ESPN ranked ZonaZoo as the top student cheering section in the PAC 12 conference and in 2015, and in 2018, ZonaZoo received the Best Student Section of the Year award from the National Collegiate Student Section Association.
=== Plastic packaging violation case === In 2011, the Supreme Court of India issued a contempt notice to Dharampal Satyapal Limited for allegedly violating a ban on the use of plastic sachets for selling products. A representative from the Centre for Public Interest Litigation, the non-governmental organisation that originally filed the petition, claimed that the company attempted to circumvent the ban by labeling plastic-packaged products as "for export only," while they were instead sold domestically.
Sources: en.wikipedia.org
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.
No. It has no approved medical indication, and human safety and efficacy data are limited. It appears in research chemical markets and is banned by some sports authorities.
Natural ligands include heme and certain metabolites; SR9009 is a synthetic small molecule with higher potency and selectivity in some assays. Its effects depend on cell type and timing. It is not a naturally occurring compound.
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.